Ultrahigh resolution profiles lead to more detailed serum peptidome signatures of pancreatic cancer

Publication date: March 2014 Source:Translational Proteomics, Volume 2 Author(s): Simone Nicolardi , Berit Velstra , Bart J. Mertens , Bert Bonsing , Wilma E. Mesker , Rob A.E.M. Tollenaar , André M. Deelder , Yuri E.M. van der Burgt Mass spectrometry-based (clinical) proteomics has been widely applied as a technology to find and validate disease-specific protein signatures. MALDI-based peptidome profiles provide a suitable platform for classification of body fluids or tissues, albeit at the cost of being unable to observe low abundant species. Here we show that a fully automated one-step solid-phase extraction serum sample cleanup in combination with fast MALDI acquisition and ultrahigh precision 15T FTICR readout provides a powerful, fast and robust approach for obtaining biomarker signatures. This is exemplified for a cohort of pancreatic cancer patients. Specific “early cancer” symptoms such as pain, jaundice or weight loss are often not experienced, thus delaying diagnosis of the disease. Novel markers for early diagnosis of pancreatic cancer are therefore urgently needed. A total of 273 serum samples, distributed over a calibration and validation set, were processed and mass analyzed within a time frame of 24h. In both sets sensitivity and selectivity values were well above 85%. In these “next-generation” MALDI peptidome profiles all species up to 9kDa were isotopically resolved. Finally, it is noted that the low ppm mass accuracy of peptides and pr...
Source: Translational Proteomics - Category: Biomedical Science Source Type: research